CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary Objectives:
- To determine the feasibility, activity, and toxicity of a novel regimen using a
concurrent irinotecan (CPT-11)/cisplatin and celecoxib combination for patients with
unresectable NSCLC.
- To determine the maximal tolerance dose of celecoxib in patients with unresectable NSCLC
treated with irinotecan/cisplatin and concurrent thoracic radiation therapy.
- To correlate the COX-2 expression and other biomarkers with response to the treatment in
the tumor from a pretreatment biopsy specimen.